Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colonoscopy & upper endoscopy cases in North Dakota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 1% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 58 | 10,547 | 20% |
| 2020 | 46 | 9,968 | 22% |
| 2021 |
Diagnostic and therapeutic colonoscopy and EGD; identifies every active endoscopist. Professional codes (what the surgeon bills): CPT 45378, 45380, 45385, 45390, 43239, 43235, 43251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 57% of the cases CMS names in North Dakota; 20 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| ERCP & endoscopic ultrasound | 7 | 463+12%/yr | +12%/yr | 4.71.2× | 0% | 800 in 2030+9.4%/yr |
| Bronchoscopy & lung nodule |
Colonoscopy & upper endoscopy in every state, and its device makers · Every procedure market in North Dakota · Every state · Compare with Illinois
| 2024 |
| 10,191 |
| 37% |
| 2025 est. | ≈ 10,300 | – |
| 2026 est. | ≈ 10,600 | – |
| 48 |
| 11,537 |
| 25% |
| 2022 | 48 | 11,209 | 29% |
| 2023 | 48 | 10,292 | 34% |
| 2024 | 47 | 10,191 | 37% |
| 2025 from claims | – | 10,347 9,496–10,948 | 39% |
| 2026 forecast | – | 10,635 9,357–12,272 | 38% |
| 2027 forecast | – | 10,727 9,171–12,784 | 39% |
| 2028 forecast | – | 10,819 9,027–13,247 | 40% |
| 2029 forecast | – | 10,909 8,910–13,681 | 41% |
| 2030 forecast | – | 10,998 8,811–14,094 | 41% |
In 2025, 11% inpatient hospital, 72% hospital outpatient, 16% surgery center.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~10,600 | ~1,200 | ~7,700 | ~1,700 |
| 2027 · ~10,700 | ~1,200 | ~7,800 | ~1,800 |
| 2028 · ~10,800 | ~1,200 | ~7,800 | ~1,800 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| 134,256−3.1%/yr |
| −3.1%/yr |
| 126.7 |
| 38% |
| 138,100 in 2030+0.5%/yr |
| Michigan | 560 | 87,395−7.5%/yr | −7.5%/yr | 108.4 | 36% | 82,100 in 2030−1%/yr |
| Indiana | 415 | 79,616−4.3%/yr | −4.3%/yr | 117.3 | 30% | 80,600 in 2030+0.2%/yr |
| Missouri | 371 | 72,989−5%/yr | −5%/yr | 122.5 | 27% | 74,000 in 2030+0.2%/yr |
| Wisconsin | 332 | 60,336−2.2%/yr | −2.2%/yr | 111.6 | 20% | 63,900 in 2030+1%/yr |
| Minnesota | 399 | 47,636−3.7%/yr | −3.7%/yr | 109.9 | 35% | 59,400 in 2030+3.8%/yr |
| Kansas | 167 | 36,685−2%/yr | −2%/yr | 93.1 | 28% | 39,000 in 2030+1%/yr |
| Iowa | 161 | 33,135−2.3%/yr | −2.3%/yr | 76.7 | 39% | 35,000 in 2030+0.9%/yr |
| Nebraska | 135 | 27,462−1.7%/yr | −1.7%/yr | 108.2 | 51% | 28,600 in 2030+0.7%/yr |
| South Dakota | 70 | 15,668−1.4%/yr | −1.4%/yr | 124.2 | 20% | 16,700 in 2030+1%/yr |
| 6 |
| 329+11%/yr |
| +11%/yr |
| 3.30.9× |
| 0% |
| 750 in 2030+15%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 94% of company spending on these surgeons in 2025, +52 pts on 2024.
In 2025, 3 companies reported engagement with North Dakota’s surgeons worth $1,382 in consulting, speaking, meals and travel tied to these products, about $29 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.